ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2396

A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases

Gerber Gomez1, Yipeng Cheng2, Kristiana Nita2, Michael Hausmann3, Christian Fischer1 and Yasemin Ataman-Önal3, 1Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland, 2AliveDx, Edinburgh, United Kingdom, 3AliveDx Suisse SA, Eysins, Switzerland

Meeting: ACR Convergence 2025

Keywords: Autoantibody(ies), autoimmune diseases, Biomarkers, Sjögren's syndrome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Detection of relevant autoantibodies is key in the identification of autoimmune connective tissue diseases (CTD). The evaluation of multiple autoantibodies for extended serological profiling may improve the diagnosis of these conditions. We evaluated the diagnostic utility, in patients with CTD and disease controls, of machine learning classifiers based on the 15-autoantibody profile performed by a novel, single-use, multiplexed microarray immunoassay, used with its fully automated high-throughput proprietary system for simultaneous the detection of IgG autoantibodies directed to dsDNA, SS-A 60, TRIM21 (SS-A 52), SS-B, Sm, Sm/RNP, U1RNP, Jo-1, Scl-70, Centromere B, Chromatin, Ribosomal P, DFS70, RNAP III and CCP2.

Methods: De-identified sera from 475 patients diagnosed with autoimmune CTD in accordance with current guidelines [127 patients with systemic lupus erythematosus (SLE), 74 with systemic sclerosis, 76 with Sjögren’s syndrome (SjS), 71 with idiopathic inflammatory myopathies, 54 with mixed CTD, 73 with rheumatoid arthritis] and 652 patients with other disorders, who served as disease controls were analyzed using the investigational MosaiQ AiPlex® CTDplus (AliveDx, Switzerland) assay. Classification models were developed using all 15 autoantibodies or a selected subset, employing the RandomForest algorithm (XGBoost and Logistic L1 L2 were also used). Diagnostic performance was evaluated by receiver operating characteristic (ROC) curve analysis.

Results: A RandomForest classifier incorporating all 15 autoantibodies demonstrated robust performance in predicting SLE, achieving an area under the curve (AUC) of 0.92. In comparison, the individual SLE-specific markers dsDNA and Sm yielded lower AUCs of 0.68 and 0.60, respectively. For SjS, the 15-plex RandomForest classifier achieved an AUC of 0.83, outperforming a 3-plex RandomForest classifier based on SS-A 60, TRIM21, and SS-B autoantibodies, which had an AUC of 0.62. The individual AUCs for these markers were 0.63, 0.59, and 0.58, respectively. Similarly, for other CTDs, 15-plex classifiers consistently outperformed the individual disease-specific markers.

Conclusion: Multiplex autoantibody testing combined with machine learning algorithms has the potential to improve the diagnosis of autoimmune CTD.

Supporting image 1Figure 1. Model Pipeline

Supporting image 2Figure 2. ROC Curves and AUCs – SLE: All 15 analytes vs. 9 Outcome-related analytes*

Supporting image 3Figure 3. ROC Curves and AUCs – SjS: All 15 analytes vs. 3 Outcome-related analytes*


Disclosures: G. Gomez: AliveDx, 3; Y. Cheng: AliveDx, 3; K. Nita: AliveDx, 3; M. Hausmann: AliveDx, 3; C. Fischer: AliveDx, 3; Y. Ataman-Önal: AliveDx, 3.

To cite this abstract in AMA style:

Gomez G, Cheng Y, Nita K, Hausmann M, Fischer C, Ataman-Önal Y. A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-machine-learning-algorithm-based-on-a-15-autoantibody-profile-by-a-novel-fully-automated-multiplexed-microarray-immunoassay-for-the-diagnosis-of-autoimmune-connective-tissue-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-machine-learning-algorithm-based-on-a-15-autoantibody-profile-by-a-novel-fully-automated-multiplexed-microarray-immunoassay-for-the-diagnosis-of-autoimmune-connective-tissue-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology